Merck

Hires -- up and down the ladder
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Merck drug wins FDA nod as first-line lung cancer treatment

By Ed Silverman

Pills
Pharmalot

Interfaith investor coalition pushes shareholder resolutions on drug prices

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Alkermes depression drug now looks promising, but will FDA bite?

By Ed Silverman

Insulin
Business

The insulin market is heading for a shakeup. But patients may not benefit

By Rebecca Robbins

Pharmalot

European regulators appeal rulings that prevent release of drug data

By Ed Silverman

Emma Walmsley
Pharmalot

Glaxo’s new CEO will be first female head of global drug company

By Ed Silverman

Pharmalot

Parents remain leery of schools that require HPV vaccination

By Ed Silverman

Bristol-Myers Squibb
Pharmalot

A key trial for a Bristol-Myers cancer drug fails in a ‘major surprise’

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Biogen is the latest pharma takeover target

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Valeant losing a crucial revenue tool

By Ed Silverman

Pharmalot

Merck Ebola vaccine wins speedier reviews by regulators

By Ed Silverman

Pharmalot

Merck to cut 360 R&D jobs, close one facility, and expand elsewhere

By Ed Silverman

Moderna
Business

Moderna gets $200m in expanded Merck deal

By Robert Weisman — Boston Globe

Pharmalot

Pharmalot, Pharmalittle: FDA staff questions effectiveness of Merck antibiotic

By Ed Silverman

Pharmalot

Gilead won’t have to pay $200 million in patent case because Merck lawyer lied

By Ed Silverman

Hires -- up and down the ladder
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: FDA approves Roche bladder cancer drug

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Investors tell pharma to ‘take control’ of the pricing debate

By Ed Silverman

Cash back
The Pharmalot View

Big drug maker presses for money-back guarantee that its science will work

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: China probing drug and device makers for antitrust violations

By Ed Silverman

Merck
Pharmalot

Merck fights with New Zealand over coverage of its Keytruda cancer drug

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: ‘Valeant was a sewer,’ says Berkshire’s Munger

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Valeant plans to overhaul its board

By Ed Silverman

Gardasil dose
Pharmalot

Switching to newest HPV vaccine can save billions in health care costs, study says

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Gilead ordered to pay $200m to Merck in patent row

By Ed Silverman

Pharmalot

Merck wins high-stakes battle with Gilead over hep C patents

By Ed Silverman

Hires -- up and down the ladder
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Gilead and Merck battle over hepatitis C patents

By Ed Silverman

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy